TREATMENT OF ACUTE MYELOID LEUKEMIA WITH AN HCK INHIBITOR

摘要

Treatment of acute myeloid leukemia (AML) patients with conventional chemotherapy and radiation results in complete remission but it is frequently followed by a recurrence of the disease that is resistant to chemotherapy. To target the leukemic stem cell population responsible for this relapse, a small molecule compound is described that inhibits HCK tyrosine kinase activity and eliminates the emergence of a highly aggressive AML leukemic stem cell proliferation that is believed to contribute to the relapse of AML in patients that have received chemotherapy treatment.